ArticleFrontiers in oncology2025
A sex dependent association between the history of autoimmune disease and the development of pancreatic cancer: a case-control study of 32,640 patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is a highly lethal cancer with increasing incidence and poor prognosis due to late diagnosis. While several risk factors are known, evidence on a potential role of autoimmune diseases remains limited. Given the increasing prevalence of autoimmune diseases and their association with various malignancies, this study aims to investigate their potential association with pancreatic cancer. Methods: 5,440 patients with a first diagnosis of pancreatic cancer and 27,200 propensity score matched individuals without cancer were identified from the Disease Analyzer database (IQVIA). The outcome of the study was the association between the diagnosis of pancreatic cancer and a patient´s history of autoimmune disease. Results: Inflammatory bowel disease (OR: 1.69; 95% CI: 1.34-2.12) and rheumatoid arthritis (OR: 1.20; 95% CI: 1.03-1.41) were significantly associated with increased odds of pancreatic cancer. The OR was 1.25 for systemic lupus erythematosus and 1.26 for multiple sclerosis without reaching a statistical significance. In sex-stratified analyses, inflammatory bowel disease was strongly associated with pancreatic cancer in women (OR: 2.14; 95% CI: 1.59-2.89) but not in men (OR: 1.24; 95% CI: 0.86-1.78). A positive association between rheumatoid arthritis and pancreatic cancer was also observed in women (OR: 1.26; 95% CI: 1.03-1.53) but not in men (OR: 1.09; 95% CI: 1.03-1.53-1.44). In addition, the ORs for SLE (1.82) and MS (1.45) were increased in women to a clinically relevant extent that did not reach the significance level of <0.05. A similar increase was not observed in male patients. Conclusion: Autoimmune disease may be associated with an increased risk of developing pancreatic cancer, particularly in women. This highlights the importance of addressing gender differences in medical practice, particularly in relation to disease screening and surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.